(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

G00002

(43) International Publication Date
30 May 2002 (30.05.2002)

PCT

(10) International Publication Number
WO 02/42298 A1

(51) International Patent Classification[7]: C07D 417/04, 417/14, A61K 31/427, 31/4439, 31/498, A61P 11/00

(21) International Application Number: PCT/EP01/13378

(22) International Filing Date:
19 November 2001 (19.11.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0028383.8 21 November 2000 (21.11.2000) GB

(71) Applicant *(for all designated States except AT, US)*: NOVARTIS AG [CH/CH], Lichtstrasse 35, CH-4056 Basle (CH)

(71) Applicant *(for AT only)*: NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT MBH [AT/AT], Brunner Strasse 59, A-1230 Vienna (AT)

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: PRESS, Neil, John [GB/GB], Novartis Horsham Research Centre, Wimblehurst Road, Horsham, West Sussex RH12 5AB (GB). TAYLOR, Roger, John [GB/GB], Novartis Horsham Research Centre, Wimblehurst Road, Horsham, West Sussex RH12 5AB (GB)

(74) Agent: BECKER, Konrad, Novartis AG, Corporate Intellectual Property, Patent & Trademark Dept., CH-4002 Basel (CH)

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, ZW.


(84) Designated States *(regional)*: Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR)

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette

162162

(54) Title: AMINOTHIAZOLES AND THEIR USE AS ADENOSINE RECEPTOR ANTAGONISTS



(I)

(57) Abstract: Compounds of formula (I) in free or salt form, where A is a C_6-C_{15} monovalent aromatic group R^1 is hydrogen, phenyl optionally substituted by one or more substituents selected from halogen, cyano, hydroxy, C_1-C_8-alkyl, C_1-C_8-haloalkyl, C_1-C_8-alkoxy, C_1-C_8-alkoxy-C_1-C_8-alkyl or acyloxy, or a 5- or 6- membered monovalent heterocyclic group, R^2 is hydrogen, C_1-C_8-alkyl, acyl or $CON(R^3)R^4$, provided that R^2 is C_1-C_8-alkyl, acyl or $CON(R^3)R^4$ when R^1 is hydrogen, R^3 and R^4 are each independently hydrogen, or C_1-C_8-alkyl, together with the nitrogen atom to which they are attached denote a 5- or 6- membered heterocyclic group, and Z^1, Z^2, Z^3 and Z^4 are each independently N or CR^5, at least one of them being CR^5, and R^5 is hydrogen, C_1-C_8-alkyl or C_1-C_8-alkoxy The compounds are useful as adenosine receptor antagonists, particularly in the treatment of inflammatory or obstructive airways diseases.

WO 02/42298 A1